Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy Bannerji, R., Brown, J. R., Advani, R. H., Arnason, J., O'Brien, S. M., Allan, J. N., Chavez, J. C., Barnes, J. A., Joyce, R., Ansell, S., Topp, M. S., Adriaens, L., Ufkin, M., Kostic, A., Paccaly, A., Gao, B., Trail, P. A., Lowy, I., Brownstein, C. AMER SOC HEMATOLOGY. 2016
View details for Web of Science ID 000394446804024